Eli Lilly and Company (NYSE:LLY) Trading 1.5% Higher – Here’s What Happened

Eli Lilly and Company (NYSE:LLY) rose 1.5% during mid-day trading on Monday . The company traded as high as $1,238.00 and last traded at $1,226.2240. Approximately 3,651,909 shares traded hands during trading, an increase of 13% from the average daily volume of 3,230,916 shares. The stock had previously closed at $1,208.12.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA selected Eli Lilly for its new PreCheck pilot program, which is designed to speed review of domestic manufacturing facilities. That supports Lilly’s ongoing $27 billion expansion plan and could help bring new plants online faster, a positive for long-term supply and growth. FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
• Positive Sentiment: Lilly’s Jaypirca received a positive opinion from Europe’s CHMP for chronic lymphocytic leukemia, improving the odds of broader EU approval and expanding the drug’s international commercial opportunity. Lilly’s Jaypirca receives CHMP positive opinion for CLL in Europe
• Positive Sentiment: Investor sentiment was also boosted by Lilly hitting new 52-week and all-time highs, helped by recent wins including the Jaypirca update and expanded Medicare access for Zepbound and Foundayo, which strengthens the company’s obesity-drug growth narrative. Here’s Why Shares of Eli Lilly Hit an All-Time High on Friday
• Positive Sentiment: Schrödinger disclosed it will receive $57 million tied to Lilly’s Ajax acquisition, a reminder of Lilly’s active dealmaking and continued investment in pipeline assets. Schrödinger Gains $57 Million From Ajax Acquisition Deal
• Neutral Sentiment: Coverage noting that Lilly has gained roughly 6% over the past month and that analysts still see upside adds to the bullish tone, but it does not provide a new company-specific catalyst. Eli Lilly and Company (LLY) Up More Than 6% Over the Past Month, Can it Move Higher?
• Neutral Sentiment: Other articles mainly highlight Lilly’s recent breakout, new highs, and strong Street momentum rather than fresh fundamental news, reinforcing the stock’s strength but not changing the investment thesis materially. Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs

Analysts Set New Price Targets

A number of brokerages have weighed in on LLY. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 8th. Barclays increased their target price on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research note on Monday, May 4th. Bank of America raised their price target on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a research report on Tuesday, May 26th. Berenberg Bank upped their price target on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a report on Monday, June 22nd. Finally, Guggenheim reiterated a “buy” rating and set a $1,183.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, May 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,235.07.

Eli Lilly and Company Stock Up 1.5%

The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The firm has a market capitalization of $1.15 trillion, a P/E ratio of 43.56, a P/E/G ratio of 1.32 and a beta of 0.53. The stock has a fifty day moving average price of $1,036.28 and a two-hundred day moving average price of $1,021.13.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. During the same period last year, the business posted $3.34 earnings per share. The firm’s revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts forecast that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is 24.58%.

Institutional Investors Weigh In On Eli Lilly and Company

Several institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in Eli Lilly and Company by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after purchasing an additional 1,006,885 shares during the period. State Street Corp grew its stake in Eli Lilly and Company by 1.8% during the 4th quarter. State Street Corp now owns 35,361,916 shares of the company’s stock worth $38,002,744,000 after buying an additional 635,358 shares during the last quarter. Capital Research Global Investors increased its position in Eli Lilly and Company by 20.9% in the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after buying an additional 4,332,008 shares during the period. Morgan Stanley increased its position in Eli Lilly and Company by 2.7% in the fourth quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock worth $16,757,510,000 after buying an additional 407,166 shares during the period. Finally, Capital World Investors lifted its stake in Eli Lilly and Company by 0.4% in the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock valued at $16,154,619,000 after buying an additional 61,851 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.